Compugen sees 'encouraging signals' from early-stage cancer trial

TEL AVIV (Reuters) - Israeli cancer immunotherapy firm Compugen said on Monday it had positive initial results from an ongoing early-stage study of its COM701 therapy in patients with advanced solid tumours who have exhausted all standard treatments.COM701 was well-tolerated with no dose-limiting toxicities when administered alone and in combination with Bristol-Myers Squibb's cancer drug Opdivo (nivolumab), Compugen said.Furthermore, COM701 demonstrated "encouraging signals of anti-tumour..